BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36681188)

  • 1. Fusion Gene Detection in Prostate Cancer Samples Enhances the Prediction of Prostate Cancer Clinical Outcomes from Radical Prostatectomy through Machine Learning in a Multi-Institutional Analysis.
    Yu YP; Liu S; Ren BG; Nelson J; Jarrard D; Brooks JD; Michalopoulos G; Tseng G; Luo JH
    Am J Pathol; 2023 Apr; 193(4):392-403. PubMed ID: 36681188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
    Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
    Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
    [No Abstract]   [Full Text] [Related]  

  • 6. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.
    Kattan MW; Wheeler TM; Scardino PT
    J Clin Oncol; 1999 May; 17(5):1499-507. PubMed ID: 10334537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
    Hu C; Qiao X; Hu C; Cao C; Wang X; Bao J
    Cancer Imaging; 2024 Feb; 24(1):23. PubMed ID: 38326860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of outcomes after radical prostatectomy in patients diagnosed with prostate cancer of biopsy Gleason score ≥ 8 via contemporary multi (≥ 12)-core prostate biopsy.
    Hong SK; Oh JJ; Jeong SJ; Jeong CW; Kim IS; Park JM; Byun SS; Choe G; Lee HJ; Lee SE
    BJU Int; 2011 Jul; 108(2):217-22. PubMed ID: 21083642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
    Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
    J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
    Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
    Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.
    Sabbagh A; Tilki D; Feng J; Huland H; Graefen M; Wiegel T; Böhmer D; Hong JC; Valdes G; Cowan JE; Cooperberg M; Feng FY; Mohammad T; Shelan M; D'Amico AV; Carroll PR; Mohamad O
    Eur Urol Focus; 2024 Jan; 10(1):66-74. PubMed ID: 37507248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.